Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer
- 2 February 2001
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 37 (2) , 115-120
- https://doi.org/10.1016/s1040-8428(00)00107-4
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Anthracycline-Induced CardiotoxicityAnnals of Internal Medicine, 1996
- Liposome Longevity and Stability in Circulation: Effects on the in vivo Delivery to Tumors and Therapeutic Efficacy of Encapsulated AnthracyclinesJournal of Drug Targeting, 1996
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinomaClinical Oncology, 1993
- Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomesInternational Journal of Cancer, 1992
- Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipidInternational Journal of Cancer, 1992
- Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycinBritish Journal of Cancer, 1991
- Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative groupEuropean Journal of Cancer and Clinical Oncology, 1986
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979